Navigation Links
Scientists discover molecule that does double duty in stopping asthma attacks
Date:2/27/2013

BOSTON, MAScientists from Brigham and Women's Hospital are on the brink of the next treatment advancement that may spell relief for the nearly nineteen million adults and seven million children in the United States suffering from asthma. The scientists discovered two new drug targets in the inflammatory response pathway responsible for asthma attacks.

The study will be published on February 27, 2013 in Science Translational Medicine.

Researchers studied the lungs and blood of 22 people with mild and severe asthma. They saw that immune cells called natural killer cells and type 2 innate lymphoid cells played significant roles in airway inflammation in study participants with severe asthma.

Natural killer cells decreased airway inflammation by encouraging programmed cell death in immune cells called eosinophils, whereas type 2 innate lymphoid cells promoted airway inflammation by secreting cell-signaling molecules called interleukin-13.

Both mechanisms were controlled by a molecule called lipoxin A4 which is responsible for resolving inflammation. To achieve this, lipoxin A4 acted in both pro-resolving and anti-inflammatory ways. The researchers saw that lipoxin A4 encouraged natural killer cells to decrease inflammation by facilitating eosinophil cell death. Lipoxin A4 also discouraged type 2 innate lymphoid cells from promoting inflammation by blocking interleukin-13 secretion.

"Stopping airway inflammation is similar to putting out a forest fire," said Bruce Levy, MD, Pulmonary and Critical Care Medicine Division, BWH Department of Internal Medicine, senior study author. "Firefighters tackle forest fires in two waysdousing the fire with water and clearing away dry brush that could fuel the fire. Lipoxin A4 does just that to resolve inflammation. It is an airway inflammation fighter that performs the double duty of dampening pathways that ignite inflammation while at the same time clearing away cells that fuel inflammation."

In previous studies, Levy and his team discovered that lipoxin A4 production was defective in patients with severe asthma. Together with their new findings, this observation provides researchers and drug manufacturers with a new direction toward boosting lipoxin A4 in severe asthmatics when designing next-generation asthma therapies.

"Most patients with severe asthma have chronic airway inflammation that never fully resolves. This can lead to daily and often disabling symptoms despite available therapies. Our study provides new information on cellular targets that regulate inflammation and will enable the development of lipoxin-based therapeutics to decrease chronic inflammation in asthma and other diseases." said Levy.


'/>"/>

Contact: Marjorie Montemayor-Quellenberg
mmontemayor-quellenberg@partners.org
617-534-2208
Brigham and Women's Hospital
Source:Eurekalert

Related biology technology :

1. Scientists Warn of Long Term Consequences of Budget Sequestration: BioInformatics LLC Report
2. UC Santa Barbara scientists develop a whole new way of harvesting energy from the sun
3. The Elsevier Foundation, TWAS, and OWSD Honor Early Career Women Scientists in Developing Countries at the Annual AAAS Meeting
4. BioInformatics LLC New Market Report – Best Practices Guide for Advertising to Life Scientists
5. Science of Hiring: Demand for Scientists Grows 15%
6. Scientists Describe Breakthrough Technology for Brain Self-Optimization in Newly Published Paper
7. Salk scientists use Amazon Cloud to view molecular machinery in remarkable detail
8. ASU scientists unravel the mysteries of spider silk
9. Citizen Scientists Successfully Fund Groundbreaking Startup to Sequence their Microbiomes
10. Scientists design, control movements of molecular motor
11. Flexing fingers for micro-robotics: Berkeley Lab scientists create a powerful, microscale actuator
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... , ... August 18, 2017 , ... ... Equipment for the Semiconductor, MEMS, and Microfluidics Industries, announces the new Model 800E ... found more often in automated production mask aligners. OAI has already received ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... Electrospinning and Electrospraying line of nanofiber and nanoparticle fabrication ... for the lab to fully automated pilot plants and equipment for industrial ...
(Date:8/16/2017)... MN (PRWEB) , ... August 16, 2017 , ... ... our third U.S. Food and Drug Administration (FDA) inspection at our Dilworth, MN ... No 483 was issued. This inspection was conducted as part of a routine ...
(Date:8/15/2017)... ... August 15, 2017 , ... Kapstone Medical ... years of successes helping medical technology companies and inventors develop and safeguard their latest ... full-service national engineering firm with a portfolio of clients in the United States and ...
Breaking Biology Technology:
(Date:3/30/2017)... , March 30, 2017  On April 6-7, 2017, ... the Genome hackathon at Microsoft,s headquarters in ... competition will focus on developing health and wellness apps ... Hack the Genome is the first hackathon ... The world,s largest companies in the genomics, tech and ...
(Date:3/30/2017)... NEW YORK , March 30, 2017 ... by type (physiological and behavioral), by technology (fingerprint, AFIS, ... recognition, voice recognition, and others), by end use industry ... travel and immigration, financial and banking, and others), and ... Europe , Asia Pacific ...
(Date:3/28/2017)... PUNE, India , March 28, 2017 ... (Analog, IP, Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), ... Maintenance), Vertical, and Region - Global Forecast to 2022", ... 30.37 Billion in 2016 and is projected to reach ... 15.4% between 2017 and 2022. The base year considered ...
Breaking Biology News(10 mins):